Azurocidin-1: a marker of COPD severity and microbial dysbiosis
J. Pollock (Dundee, United Kingdom), A. Dicker (Dundee, United Kingdom), M. Lonergan (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), A. Smith (Dundee, United Kingdom), M. Crichton (Dundee, United Kingdom), J. Huang (Dundee, United Kingdom), B. Miller (Collegeville, PA, United States of America), R. Tal-Singer (Collegeville, PA, United States of America), J. Chalmers (Dundee, United Kingdom)
Source: Virtual Congress 2020 – Biomarkers and characterisation of immune response in respiratory infection
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Pollock (Dundee, United Kingdom), A. Dicker (Dundee, United Kingdom), M. Lonergan (Dundee, United Kingdom), H. Keir (Dundee, United Kingdom), A. Smith (Dundee, United Kingdom), M. Crichton (Dundee, United Kingdom), J. Huang (Dundee, United Kingdom), B. Miller (Collegeville, PA, United States of America), R. Tal-Singer (Collegeville, PA, United States of America), J. Chalmers (Dundee, United Kingdom). Azurocidin-1: a marker of COPD severity and microbial dysbiosis. 2340
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: